Phaseline

Companies › Ever Supreme Bio Technology

Ever Supreme Bio Technology: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 2; Oncology, Neurology, Cardiovascular, Infectious disease; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
UMSC01 cells
Allogeneic umbilical cord mesenchymal stem cells
–Phase 2ST Elevation Myocardial Infarction; COVID-19 Infection; Multiple SclerosisJun 2027
ADCV01
autologous dendritic cell vaccination
–Phase 2GBMDec 2027
HLA-G-CAR.BiTE allogeneic γδ T cells
HLA-G-targeted CAR (chimeric antigen receptor) BiTE (bispecific T cell engager) allogeneic
HLA-GPhase 1Solid TumorJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06147986UMSC01 cellsPhase 2ST Elevation Myocardial InfarctionCardiovascularJun 2027
NCT06150885HLA-G-CAR.BiTE allogeneic γδ T cellsPhase 1Solid TumorOncologyJun 2027
NCT04115761ADCV01Phase 2GBMOncologyDec 2027
NCT05501418UMSC01 cellsPhase 1COVID-19 InfectionInfectious diseaseDec 2027
NCT05532943UMSC01 cellsPhase 1Multiple SclerosisNeurologyOct 2028

Targets

HLA-G (1)

Companies with the same targets

Shine-On Biomedical Tizona Therapeutics

Companies built like this

Beijing Yongtai Ruike Biotechnology Company Hebei Senlang Biotechnology Neuboron Bio-SciTech Hrain Biotechnology Marzieh Ebrahimi

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.